Combination PI3K and NOS targeted therapy for metaplastic breast cancer

被引：0
|
作者：
Reddy, T. [1 ]
Rosato, R. [1 ]
Guzman, L. [1 ]
Qian, W. [1 ]
Zhou, J. [1 ]
Piwnica-Worms, H. [2 ]
Moulder, S. [3 ]
Chang, J. [1 ]
机构：
[1] Houston Methodist Res Inst, Ctr Canc, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Canc Biol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Breast Oncol, Houston, TX 77030 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
179
引用
收藏
页码：S49 / S50
页数：2
相关论文
共 50 条
  • [31] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, 12 (04) : 342 - 354
  • [32] Imaging tumor metabolism to guide treatment of breast cancer with drugs targeted at PI3K alpha
    Ros, Susana
    D'Santos, Paula
    Hu, De-en
    Batra, Ankita S.
    Wright, Alan J.
    Mannion, Elizabeth
    Bruna, Alejandra
    Caldas, Carlos
    Brindle, Kevin M.
    CANCER RESEARCH, 2017, 77
  • [33] Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
    Brandao, M.
    Caparica, R.
    Eiger, D.
    de Azambuja, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 27 - 42
  • [34] Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
    Coussy, F.
    El Botty, R.
    Lavigne, M.
    Gu, C.
    Fuhrmann, L.
    Briaux, A.
    de Koning, L.
    Dahmani, A.
    Montaudon, E.
    Morisset, L.
    Huguet, L.
    Sourd, L.
    Painsec, P.
    Chateau-Joubert, S.
    Larcher, T.
    Vacher, S.
    Melaabi, S.
    Salomon, A. Vincent
    Marangoni, E.
    Bieche, I.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [35] Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
    F. Coussy
    R. El Botty
    M. Lavigne
    C. Gu
    L. Fuhrmann
    A. Briaux
    L. de Koning
    A. Dahmani
    E. Montaudon
    L. Morisset
    L. Huguet
    L. Sourd
    P. Painsec
    S. Chateau-Joubert
    T. Larcher
    S. Vacher
    S. Melaabi
    A. Vincent Salomon
    E. Marangoni
    I. Bieche
    Journal of Hematology & Oncology, 13
  • [36] Tocotrienols Target PI3K/Akt Signaling in Anti-Breast Cancer Therapy
    Sylvester, Paul W.
    Ayoub, Nehad M.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (07) : 1039 - 1047
  • [37] Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy
    Han, Beinan
    Lin, Xiaorong
    Hu, Hai
    TRANSLATIONAL BREAST CANCER RESEARCH, 2024, 5
  • [38] PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
    Abraham, Jame
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 51 - 68
  • [39] PI3K A rational target for ovarian cancer therapy?
    Dent, Paul
    Grant, Steven
    Fisher, Paul B.
    Curiel, David T.
    CANCER BIOLOGY & THERAPY, 2009, 8 (01) : 27 - 30
  • [40] Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
    Garg, Pankaj
    Ramisetty, Sravani
    Nair, Meera
    Kulkarni, Prakash
    Horne, David
    Salgia, Ravi
    Singhal, Sharad S.
    BIOCHEMICAL PHARMACOLOGY, 2025, 236
12345